UCL Technology Fund — 2017 Investments

1 investments dated 2017 · listed companies and verified rows first · show all

Orchard Therapeuticsorchard-tx.com in 𝕏Dec 2017 · $110M

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.

BiotechDeep TechHealthtechMedical DevicesLondon, GB

Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)

Board Bobby Gaspar(Scientific Founder)in

Co-investorsAlbionVC F-Prime Capital Foresite Capital 4BIO Capital Agent Capital Baillie Gifford +3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.